Drug-induced Endometrial Cancer: A Pharmacovigilance Study Based on Real-World Data from the FAERS Database

This study aims to identify and evaluate drugs associated with the risk of endometrial cancer using the FDA Adverse Event Reporting System (FAERS) database. We retrieved adverse drug events (ADEs) related to drug-induced endometrial cancer from the FAERS database (Q1 2004–Q4 2024). A disproportionality analysis was conducted to identify drugs significantly associated with endometrial cancer risk, and time-to-onset (TTO) analyses were performed to assess the timing and risk profiles of adverse reactions related to endometrial cancer. Our study identified 2,352 ADEs linked to endometrial cancer. Disproportionality analysis identified 32 drugs associated with endometrial cancer risk, including 11 hormone medications, 9 cancer drugs, 2 antihypertensive drugs, 1 antiviral drug, 4 immunosuppressants, 1 mineral supplement, 1 gastrointestinal drug, and 3 osteoporosis drugs. Through a comprehensive analysis of the FAERS database, our study identified drugs strongly associated with endometrial carcinogenesis. Preventing drug-related endometrial cancer requires careful drug selection and monitoring. This study provides evidence-based insights for clinical management, aiming to optimize clinical care and mitigate risks.